Recent events
Recent events tied to this brand in public sources.
Back to profile63 entries · Page 1 of 4
2026
Abbott announces planned nutrition business spin-off
Abbott announced plans to spin off its global nutrition business as a separately listed company. The business, which includes Similac, PediaSure, Pedialyte, Glucerna and Ensure, is expected to complete the transaction by the end of 2027.
2026
Abbott announces a baby formula spinoff
Abbott Laboratories announced a baby formula spinoff company.
2026
Abbott cuts its 2026 sales growth forecast
Abbott cut its 2026 sales growth forecast to about 6%, from its previous expectation of 6.5% to 7.5%.
2024
FDA issues Class I recall for Abbott HeartMate pumps
The FDA issued its most serious recall for Abbott subsidiary Thoratec's HeartMate II and HeartMate 3 pumps, affecting nearly 14,000 devices. The devices can develop a buildup of biological material that reduces blood-flow capability; the article reports that the recall was linked by the agency to hundreds of injuries and at least 14 deaths.
2024
FDA approves Abbott's TriClip system for tricuspid regurgitation
The US Food and Drug Administration approved Abbott's TriClip transcatheter edge-to-edge repair system for treatment of tricuspid regurgitation. Abbott announced the approval on April 2, 2024.
2024
Abbott launches Protality protein shake
Abbott said it launched a protein shake under its new Protality brand, intended to help adults looking to lose weight maintain muscle mass.
2023
Abbott launches FreeStyle LibreLink app in India
Abbott launched the FreeStyle LibreLink app in India. The app lets users of the FreeStyle Libre system view glucose readings on their mobile phones without pricking.
2023
FDA approves Tibsovo for certain patients with MDS
The FDA approved Servier’s Tibsovo to treat adults with relapsed or refractory MDS with an IDH1 mutation, making it the first targeted therapy approved for this indication. The regulator also approved the Abbott RealTime IDH1 Assay as a companion diagnostic for identifying eligible patients.
2023
Abbott raises 2023 earnings guidance
Abbott raised and narrowed its adjusted diluted earnings-per-share guidance for 2023 to $4.42–$4.46, from its previous range of $4.30–$4.50.
2023
Abbott completes acquisition of Bigfoot Biomedical
Abbott announced that it completed its acquisition of Bigfoot Biomedical, which became a wholly owned subsidiary of Abbott upon completion.
2023
Abbott launches Vertigo Coach app in India
Abbott launched the Vertigo Coach app in India to provide people with vertigo information and resources to help manage their condition.
2023
Lawsuit filed over PediaSure height claims
Joanne Noriega filed a proposed class action against Abbott Laboratories, alleging that the company misled consumers into believing PediaSure drinks were clinically proven to increase children's height. Abbott said the case was without merit and defended the product's nutritional claims.
2023
Abbott and Norton Healthcare launch clinical research initiative
Abbott announced a new initiative with the Norton Healthcare Foundation and the Institute for Health Equity at Norton Healthcare to build and implement sustainable clinical research models for historically Black colleges and universities and clinics serving under-represented communities.
2023
Abbott partners with Barnett International on coordinator training
Abbott announced a partnership with Barnett International to provide an education program training clinical research coordinators from diverse backgrounds who will work with under-represented communities.
2023
Abbott makes FreeStyle Libre 3 available in UK insulin delivery system
Abbott made its FreeStyle Libre 3 blood sugar sensor available in the U.K. as part of an automated insulin delivery system that combines the sensor with Ypsomed’s connected pump and a CamDiab-developed mobile app.
2023
Abbott completes acquisition of Cardiovascular Systems, Inc.
Abbott announced it completed the acquisition of Cardiovascular Systems, Inc. (CSI), which became Abbott’s wholly owned subsidiary upon completion.
2023
Abbott announced plans to acquire Cardiovascular Systems
Abbott announced plans to acquire Cardiovascular Systems for $20 per share, an approximately $890 million deal. The companies said the transaction would require regulatory and shareholder approvals; it had not yet been completed.
2023
Abbott announces investment in Ohio formula plant
Abbott said it would invest $536 million in a new plant in Bowling Green, Ohio, to produce powdered nutritional and specialty products. The plant was expected to be operational by 2026.
2022
Abbott launches Eterna spinal cord stimulator in the U.S.
Abbott announced the U.S. launch of its Eterna rechargeable spinal cord stimulation device, described as its smallest rechargeable implant of this kind.
2022
Abbott receives three CES 2023 Innovation Awards
Abbott received three CES 2023 Innovation Awards from the Consumer Technology Association for its Aveir VR leadless pacemaker, Proclaim Plus SCS system, and Alinity m Monkeypox PCR test.